Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trial
Helena M Earl, Anne-Laure Vallier, Louise Hiller, Nicola Fenwick, Jennie Young, Mahesh Iddawela, Jean Abraham, Luke Hughes-Davies, Ioannis Gounaris, Karen McAdam, Stephen Houston, Tamas Hickish, Anthony Skene, Stephen Chan, Susan Dean, Diana Ritchie, Robert Laing, Mark Harries, Christopher Gallagher, Gordon Wishart Show all
Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2014
Awarded by Cancer Research UK
Awarded by National Institute for Health Research
Funding Cancer Research UK, Eli Lilly, Bristol-Myers Squibb.